AADI Aadi BiosciencesWatchlist
About Aadi Biosciences Company
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
LOS ANGELES, Sept. 20, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today
Aadi Biosciences(AADI.US) Officer Sells US$238.83K in Common Stocks
$Aadi Biosciences(AADI.US)$ Officer Desai Neil sold 42,000 shares of Common Stocks on Sep 1, 5, 6, 2023 at an average price of $5.6863 for a total value of $238.83K.Source: Announcement What is statem
We're Not Very Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Rate
• $Red Robin(RRGB.US)$ +13.8% (In reaction to earnings)
• $PMV Pharmaceuticals(PMVP.US)$ +11.2% (ASCO-related announcement)
• $Sumo Logic(SUMO.US)$ +10.8% (In reaction to earnings)
• $Adicet Bio(ACET.US)$ +9.6% (ASCO-related announcement)
• $Dell Technologies(DELL.US)$ +9.6% (In reaction to earnings)
• $ImmunoGen(IMGN.US)$ +8.7% (ASCO-related announcement)
• $Ulta Beauty(ULTA.US)$ +7.9% (In reaction to earnings)
• $Zymergen(ZY.US)$ +7.8% (to...